Novavax, Inc.

Published Date: 13/06/2011
Category: Therapies & Markets

Research Report Decription

Novavax, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, detailed financials, and corporate actions, providing a 360˚ view of the company.

Features:

• Detailed information on Novavax, Inc. required for business and competitor intelligence needs
• A study of the major internal and external factors affecting Novavax, Inc. in the form of a SWOT analysis
• An in-depth view of the business model of Novavax, Inc. including a breakdown and examination of key business segments
• Five-year financial information and charts, including balance sheet, income statement, cash flows, market capitalization and multiples, and key ratios for Novavax, Inc.
• Intelligence on Novavax, Inc.nv’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
• News about Novavax, Inc., such as business expansion, restructuring, and contract wins
• Large number of easy-to-grasp charts and graphs that present important data and key trends

Key Questions Answered:

• Gain understanding of the Novavax, Inc. and the factors that influence its strategies 
• Track strategic initiatives of the company and latest corporate news and actions 
• Assess Novavax, Inc. as a prospective partner, vendor or supplier
• Support sales activities by understanding your customers' businesses better
• Stay up to date on Novavax, Inc.’s business structure, strategy and prospects

Companies Mentioned:

Novavax, Inc.

Paper Highlights:

Novavax is a biopharmaceutical company focused on developing recombinant vaccines. The company's technology platform is based on the virus-like particles (VLPs). The company primarily operates in the US. It is headquartered in Rockville, Maryland and employs 93 people.The company recorded revenues of $0.3 million (approximately $0.3 million) during the financial year (FY) ended December 2009, a decrease of 72.7% over FY2008. The decrease in revenues was primarily due to lower contract research and development revenues primarily as a result of timing of work under a government contract. The operating loss of the company was $38.4 million during FY2009, as compared to the operating loss of $36.3 million in FY2008. The net loss of the company was $38.4 million in FY2009, as compared to the net loss of $36 million in FY2008.